|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
1900 Alameda De Las Pulgas,San Mateo,California,US
|
|
Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. T-LITEs incorporate a small molecule-controlled switch into a conventional bispecific t-cell engaging antibody which enables precise on/off control over the timing and magnitude of redirected T-cell cytotoxic activity. Soteria was founded in 2018 with technology licensed from UC San Francisco and is based in San Francisco, California.
|
Soteria Biotherapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Soteria Biotherapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Soteria Biotherapeutics customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.